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Translational relevance 59 
Urothelial bladder cancer (UBC) remains the second most frequent cause of mortality among 60 
genitourinary cancers. Due to high relapse rates, frequent patient monitoring is required, 61 
leading to augmented associated healthcare costs and diminished patient compliance. A 62 
prevailing need for non-invasive biomarkers which will facilitate the timely diagnosis of 63 
primary and recurrent UBC remains unmet to date. This study is focused on the investigation 64 
of biomarker panels based on urinary peptides, as screening tools for the diagnosis of 65 
urothelial bladder cancer. Two biomarker panels were developed for primary and recurrent 66 
UBC, by employing 1357 urine samples. Further validation of the peptide panels in patients 67 
representing primary and surveillance settings resulted in AUCs (area under the Receiver 68 
Operating Characteristic curve) of 0.87 and 0.75, respectively. In reference to the peptide 69 
biomarker model for detection of recurrence, combination with cytology increased the AUC 70 
to 0.87. 71 
 72 
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 78 
Abstract 79 
Purpose: Urothelial bladder cancer (UBC) presents high recurrence rates, mandating 80 
continuous monitoring via invasive cystoscopy. The development of non-invasive tests for 81 
disease diagnosis and surveillance remains an unmet clinical need. In this study, validation of 82 
two urine-based biomarker panels for detecting primary and recurrent UBC was conducted. 83 
Experimental Design: Two studies (total n=1357) were performed for detecting primary 84 
(n=721) and relapsed UBC (n=636). Cystoscopy was applied for detecting UBC, while 85 
patients negative for recurrence had follow-up for at least one year to exclude presence of an 86 
undetected tumor at the time of sampling. Capillary electrophoresis coupled to mass 87 
spectrometry (CE-MS) was employed for the identification of urinary peptide biomarkers. 88 
The candidate urine-based peptide biomarker panels were derived from nested cross-sectional 89 
studies in primary (n=451) and recurrent (n=425) UBC. 90 
Results: Two biomarker panels were developed based on 116 and 106 peptide biomarkers 91 
using support vector machine algorithms. Validation of the urine-based biomarker panels in 92 
independent validation sets, resulted in AUC values of 0.87 and 0.75 for detecting primary 93 
(n=270) and recurrent UBC (n=211), respectively. At the optimal threshold, the classifier for 94 
detecting primary UBC exhibited 91% sensitivity and 68% specificity, while the classifier for 95 
recurrence demonstrated 87% sensitivity and 51% specificity. Particularly for patients 96 
undergoing surveillance, improved performance was achieved when combining the urine-97 
based panel with cytology (AUC of 0.87). 98 
Conclusions: The developed urine-based peptide biomarker panel for detecting primary UBC 99 
exhibits good performance. Combination of the urine-based panel and cytology resulted in 100 
improved performance for detecting disease recurrence.  101 
 102 
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  104 
1. Introduction 105 
Urinary bladder cancer (UBC) remains the second most frequent cause of mortality among 106 
genitourinary cancers, including approximately 430,000 incident cases and 165,000 107 
attributable deaths annually worldwide (1). The striking majority of malignant bladder 108 
tumours are of epithelial origin. Depending on the degree of tumour infiltration in the vesical 109 
wall, 80% of neoplasms are classified as non-muscle invasive (NMIBC), while the remainder 110 
are muscle invasive (MIBC) tumours (2). Following initial treatment, up to 70% of NMIBC 111 
patients experience disease recurrence (3, 4). Current approaches for detecting both primary 112 
and recurrent disease rely on invasive cystoscopy. However, due to high UBC relapse rates 113 
(4) frequent patient monitoring is required (3), leading to diminished patient compliance and 114 
augmented associated healthcare costs (5). In an effort to reduce the frequency of 115 
cystoscopies conducted, several non-invasive biomarkers have been approved by the U.S. 116 
Food & Drug Administration, albeit with performance rates remaining insufficient to replace 117 
current diagnostic and monitoring practices relying on cystoscopy (6). Therefore, a prevailing 118 
need for non-invasive biomarkers which will facilitate the timely diagnosis of primary and 119 
recurrent UBC (6), including low-grade NMIBC (7, 8), remains unmet to date. Such 120 
biomarkers are likely to reduce the frequency of diagnostic cystoscopies conducted, 121 
particularly among patients undergoing monitoring for recurrent UBC. 122 
Capillary electrophoresis coupled to mass spectrometry (CE-MS) has been applied for the 123 
investigation of peptides and low molecular weight proteins (≤20kDa) as urinary biomarkers 124 
(9, 10). The biomarkers can be subsequently sequenced and identified by employing CE-125 
MS/MS and LC-MS/MS proteomics platforms (11). Taking advantage of existing ample sized 126 
peptide databases available for conducting in-depth biomarker assessment (10), support vector 127 
machines (SVM), shown to be more efficient in the analysis of such complex proteomics 128 
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datasets in comparison to unsupervised methods (12),  are used to generate high-dimensional 129 
biomarker classifiers (namely biomarker panels) which exhibit superior accuracy to single 130 
protein markers (9, 11, 13-15).  131 
Particularly for UBC, CE-MS based biomarker panels have been previously described, 132 
exhibiting discriminatory capabilities for primary UBC (15), nevertheless at advanced stages 133 
(13). The present multi-center study aims to expand upon these initial efforts targeting to 134 
discover and validate urinary biomarker panels for detecting primary and recurrent UBC. 135 
 136 
2. Patients and Methods  137 
2.1 Patient enrollment and urine collection  138 
Two multi-center cross-sectional studies were conducted to investigate the study objectives 139 
according to the REMARK Reporting Recommendations (16) and the recommendations for 140 
biomarker identification and reporting in clinical proteomics (17). A schematic representation 141 
of the study design is depicted in Figure 1. The study was performed in accordance with the 142 
Declaration of Helsinki and ethical approval was obtained by local Ethics Committees. Proper 143 
informed consent procedures under Institutional Review Board approved protocols were 144 
followed. Urine samples were collected in the period 2003-2014 from eligible outpatients 145 
visiting the Hospital del Mar in Barcelona, Spain (n=526), Erasmus Medical Center in 146 
Rotterdam, The Netherlands (n=456), University Hospital of Virginia, USA (n=304), Laikon 147 
Hospital in Athens, Greece (n=47) and Hannover Medical School, Germany (n=24). Voided 148 
midstream urine was collected at outpatient visit and prior to any treatment, according to the 149 
standard protocol for urine collection defined by the European Kidney and Urine Proteomics 150 
(EuroKUP) and Human Kidney and Urine Proteome Project (HKUPP) networks. All urine 151 
samples were collected prior to cystoscopy and stored immediately following sample 152 
collection at -20°C until CE-MS analysis was performed. Presence of UBC was confirmed 153 
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with on-site cystoscopy. Among UBC patients, tumour stage and grade was defined according 154 
to the TNM (tumour nodes metastases) classification (18), following histological examination 155 
of biopsied tumor specimens. To avoid misclassification bias, all patients were re-evaluated 156 
for at least one year following baseline assessment.  157 
 158 
2.2 Study cohort for Primary UBC  159 
For assessing primary UBC, 721 eligible participants, including 509 primary UBC patients 160 
and 212 urological controls were evaluated.  The latter included patients presenting with 161 
hematuria and patients suffering from other disorders of the genitourinary tract, such as acute 162 
cystitis and nephrolithiasis (Supplementary Table S1). Exclusion criteria were presence of 163 
adenocarcinoma and papillary carcinoma (n=5). Forty-seven urine samples (random-catch) 164 
were collected at Laikon Hospital in Athens, Greece; 304 urine samples were from patients 165 
enrolled in the Department of Urology of University of Virginia, Charlottesville, USA. 166 
Eighty-five urine samples were from patients undergoing cystoscopy at the Erasmus MC, the 167 
Netherlands; 267 from Hospital del Mar in Barcelona, Spain, and 18 samples were from 168 
patients visiting the Hannover Medical School, Germany. All patients were primary referrals, 169 
with no prior history of any urinary tract malignancy. The UBC patients received the 170 
following treatment: radical cystectomy (MIBC patients) and TUR-B (NMIBC patients).  The 171 
primary cohort of 721 patients (mean age of 66±13 years) was randomly separated in 172 
discovery and validation sets of 451 (mean age of 66±13 years) and 270 (mean age of 68±12 173 
years) patients, respectively. The frequencies of the various stages were similar in the 174 
discovery and validation sets. 175 
 176 
2.3 Study cohort for patients undergoing surveillance 177 
 For evaluating recurrent UBC, 763 patients undergoing UBC recurrence monitoring, 178 
according to the EORTC risk assessment and EAU guidelines (3), were evaluated 179 
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(Supplementary Table S2). A total of 447 voided urine samples were collected from patients 180 
undergoing cystoscopy in at the Erasmus MC, the Netherlands. Similarly, 310 urine samples 181 
were derived from patients attending the Hospital del Mar in Barcelona and 6 urine samples 182 
from Hannover Medical School, Germany. Among the 763 patients undergoing UBC 183 
recurrence monitoring, UBC was confirmed by cystoscopy and histological diagnosis in 164 184 
cases. Out of these 164 relapses, 136 were NMIBC and 28 MIBC cases. Exclusion criteria 185 
were presence of adenocarcinoma and papillary carcinoma (n=9). Negative cystoscopy 186 
(n=599) was used to exclude recurrence and define controls in this population under 187 
surveillance. Controls with follow-up for less than 1 year or relapse within 1 year from 188 
sampling were excluded to rule out false negatives at the time of sampling. In total, 127 189 
patients had to be excluded based on the above criteria and the remaining 472 urine samples 190 
were included in the analysis. The surveillance cohort (164 confirmed UBC cases and 472 191 
eligible negative for recurrence controls) presented a mean age of 68 years (SD=±12) and was 192 
separated in a discovery set (n=425; mean age of 69±12) and a validation set (n=211; mean 193 
age of 68±13).  194 
The distribution of the different disease stages was similar in the discovery and validation 195 
sets. In addition, 55 urine samples (out of the 211 validation set samples) originated from 196 
UBC positive cases, of which 14 or 6.6% were confirmed with MIBC.  197 
Information on supplementary treatment [intravesical Bacillus Calmette-Guerin treatment 198 
(BCG), Epirubicin (Epi) or Mitomycin C (MMC)] prior to the urine collection was available 199 
for 371 patients undergoing UBC recurrence monitoring from those attending the Erasmus 200 
MC (Supplementary Table S2). The distribution of these treatment modalities was similar in 201 
the discovery and validation sets [discovery set included 21.1% treated (out of which 1.6% 202 
was BCG, 1.6% MMC, and 17.9% EPI) and 78.9% non-treated; validation set included 21.0% 203 
treated (out of which 1.4% was BCG, 0.4 MMC, and 18.1% Epi) and 79.0% non-treated, 204 
p=0.6229, Chi-squared test], as shown in the Supplementary Table S2. 205 
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Of the 211 subjects that were included in the validation phase, voided urinary cytology (VUC) 206 
results were available for 96 urinary samples.  207 
 208 
2.4 Sample preparation and CE-MS analysis  209 
Sample preparation was performed according to a standardized protocol (19). Data acquisition 210 
was performed by employing a P/ACE MDQ capillary electrophoresis system (Beckman 211 
Coulter, Fullerton, USA) coupled on-line to a Micro-TOF MS (Bruker Daltonic, Bremen, 212 
Germany), following the previously described sample injection and acquisition protocol  (15). 213 
Accuracy, precision, selectivity, sensitivity, reproducibility, and stability have been 214 
previously reported (15, 20). Mass spectral ion peaks representing identical molecules at 215 
different charge states were de-convoluted into single masses using the MosaiquesVisu 216 
software (21). Normalization of the CE-MS data was performed by using 29 internal peptide 217 
standards (10, 13). Detected peptides were deposited, matched, and annotated in a Microsoft-218 
SQL database.  219 
 220 
2.5 Statistical Analysis  221 
Discovery Phase: Statistical analysis was performed for identifying discriminatory 222 
biomarkers for primary and recurrent UBC, by analysing the two discovery sets separately.  223 
Peptide intensities were log-transformed, and their difference between cases and controls was 224 
evaluated by using the Wilcoxon rank-sum test. To eliminate potential center bias, the 225 
biomarkers were further analyzed for their correlation with primary or recurrent UBC across 226 
the various participating clinical centers. All the peptides fulfilling at least one of the two 227 
following criteria: a) significant after multiple testing adjustment using Benjamini-Hochberg 228 
and/or b) consistent in regulation in at least two clinical centers, were shortlisted. Considering 229 
that the significant biomarkers should display differences associated with UBC disease as a 230 
whole, and in order to increase the SVM statistical power, a pool of significant UBC 231 
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associated peptides were shortlisted. Using these later shortlisted peptides, two urine-based 232 
biomarker panels were optimized in the two separate training sets, using the SVM-based 233 
MosaCluster software (version 1.7.0) (12, 22). The MosaCluster software tool allows for the 234 
classification of samples in the high dimensional parameter space by using SVM algorithms, 235 
previously shown to be particularly effective in analyzing high dimensional proteomics 236 
datasets (22, 26). The software generates a classifier, based on predefined peptides. Each of 237 
these peptides allegorizes one dimension in the n-dimensional parameter space (23, 24). 238 
Specifically, the following SVM parameters were defined and further applied during 239 
validation: for the Primary UBC classifier: C=5.04494, gamma=0.008269, epsilon=0.001; and 240 
for the Recurrent UBC classifier: C=6.40000, gamma=0.008000, epsilon=0.001. 241 
 242 
Validation Phase: The urine-based biomarker panels were subsequently validated for 243 
detecting primary or recurrent UBC in the independent validation sets of 270 and 211 244 
samples, respectively. Sensitivity and specificity of the SVM-based classifier were estimated 245 
based on the number of correctly classified samples, as defined by cystoscopy (12). The 246 
biomarker score was calculated via SVM-based software, MosaCluster (version 1.7.0). 247 
Confidence intervals (95% CI) were based on exact binomial calculations and were calculated 248 
in MedCalc® Version 12.1.0.0 (Mariakerke, Belgium), as were the receiver operating 249 
characteristic (ROC) plots. The area under the ROC curve (AUC) was evaluated for 250 
estimating the overall accuracy (25). Statistical comparisons of the validation classification 251 
scores between the UBC patients and the control groups, was performed by the Kruskal-252 
Wallis test using MedCalc®. For the UBC patients, the classification scores according to the 253 
tumor stages were also investigated. Negative and positive predictive values (NPV/PPV), 254 
were calculated accounting for the specific prevalence rates for primary and recurrent disease 255 
in this study. 256 
 257 
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2.6 Sequencing of peptides 258 
Urine samples were analyzed on a Dionex Ultimate 3000 RSLS nanoflow system (Dionex, 259 
Camberly UK) coupled to an Orbitrap Velos instrument (Thermo Scientific) (26). The data 260 
files were analyzed using Proteome Discoverer 1.2 (activation type: HCD; min-max precursor 261 
mass: 790-6000 Da; precursor mass tolerance: 10 ppm; fragment mass tolerance: 0.05 Da; 262 
S/N threshold: 1) and were searched against the Uniprot human non-redundant database 263 
without enzyme specificity. No fixed modifications were selected, oxidation of methionine 264 
and proline were selected as variable modifications. The criteria for accepting sequences were 265 
high confidence (Xcorr≥1.9), absence of unmodified cysteine and absence of oxidized proline 266 
in protein precursors other than collagens or elastin. For further validation of obtained peptide 267 
identifications, the strict correlation between peptide charge at the working pH of 2.0 and CE-268 
migration time was used to prevent false identifications (27).  269 
 270 
3. Results 271 
3.1 Identification of significant urinary biomarkers for UBC 272 
For assessing primary UBC, a case-control comparison was conducted in the 451 urine 273 
samples of the discovery set, between 341 primary UBC cases and 110 urological controls. 274 
The statistical comparison enabled the identification of 329 apparently significant peptides 275 
(p<0.05, Wilcoxon rank-sum test), shown in Supplementary Table S3. Among those 329, 9 276 
peptides were statistically significant after adjustment for FDR by using Benjamini Hochberg 277 
test (Supplementary Table S3). To further increase the validity of the findings, the 329 278 
biomarkers were assessed for concordant regulation across the different clinical centers. For 279 
the primary cohort, 62 potential biomarkers were identified as being concordant in the 280 
regulation trend in at least two clinical centers (Supplementary Table S3). Combination of 281 
the 9 peptides significant after multiple testing adjustment and the 62 peptides that were 282 
identified with concordant regulation in at least two clinical centers resulted in 66 unique 283 
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peptide biomarkers, apparently significantly associated with the disease. These were included 284 
in a peptide panel using the SVM-based software. The biomarker panel exhibited 76% 285 
diagnostic accuracy and an estimated AUC value of 0.77 after complete take-one out cross-286 
validation in the training set of 451 samples. For investigating recurrent UBC, comparison 287 
was performed between the 109 recurrent UBC cases and 316 negative for recurrence 288 
controls. In detail, 327 biomarkers were identified as apparently significantly altered. Among 289 
the latter, 51 were significant after multiple adjustment using the Benjamini Hochberg test. As 290 
described above, the regulation of the 327 potential biomarker peptides was subsequently 291 
examined for their regulation in the different clinical cohorts (Supplementary Table S4). In 292 
total, 25 peptides were identified as concordantly regulated in the different clinical centers, as 293 
shown in Supplementary Table S4. Among the 25 with concordant regulation in the 294 
recurrent cohort, 13 had already been shortlisted as remaining statistical significant after 295 
multiple adjustment using Benjamini Hochberg. Therefore, the combination of the 25 296 
consistently regulated peptides with the 51 peptides remaining significant after multiple 297 
comparison adjustment resulted in 63 unique peptide biomarkers. These were subsequently 298 
combined in a multiple-peptide SVM-based panel. The diagnostic accuracy was initially 299 
assessed using cross-validation in the training set of 425 urine samples. The estimated AUC 300 
value was 0.70 after complete take one out cross validation. Both the biomarker panels 301 
apparently exhibited satisfactory performance when cross-validated in the two separate 302 
training sets. Considering that classifiers based on a higher number of biomarkers regularly 303 
show increased stability and performance (12), in the next step all possible available 304 
biomarkers (pooling all potential peptide biomarkers defined above, 66 for primary and 63 for 305 
recurrent UBC (including 4 overlapping peptides) were employed aiming to establish SVM-306 
based UBC-specific classifiers with superior performance. Using the pool of these 125 307 
biomarkers and the SVM-based MosaCluster software, two biomarker panels were generated 308 
and optimised using a take-one-out procedure and the two separate training sets of 451 309 
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(primary) and 425 (surveillance) urine samples, respectively. In the former (discovery set of 310 
451 urine samples from patients with primary UBC), 116 peptides were employed to form an 311 
optimized SVM-based biomarker classifier (Supplementary Table S5). Similarly, during the 312 
optimization of the SVM model for recurrence, out of the 125 peptides, a peptide panel based 313 
on 106 peptides (coinciding with 116-peptide model for primary UBC minus ten hemoglobin 314 
peptide sequences that were proven to carry no value in detecting recurrence) was developed. 315 
Both the aforementioned peptide panels (116-peptide model for primary and 106-peptide 316 
model for recurrence) exhibited better diagnostic accuracies that the initially developed panels 317 
(66-peptide model for primary and 63-peptide model for recurrence). This was indicated by 318 
AUC value of 0.88 for detection of primary UBC after cross-validation in the training set and 319 
AUC value of 0.76 after cross-validation in the recurrent training cohort. Based on these 320 
results, the 116-peptide panel for detecting primary UBC and the 106-peptide panel for 321 
detecting recurrent UBC were chosen for further validation in the independent validation sets.  322 
 323 
3.2 Validation of the UBC biomarker panel for detecting primary UBC 324 
Subsequent validation of the 116 peptide biomarker panel was conducted in an independent 325 
set of 270 samples (including 168 primary UBC cases and 102 controls) resulting in an AUC 326 
of 0.87, (95% CI: 0.83-0.91). At a cut-off level of -0.27, which was selected to allow for high 327 
sensitivity in UBC detection, the biomarker panel’s sensitivity was estimated at 91% with 328 
specificity of 68%, respectively (Figure 2A). Considering a prevalence rate of 63.5%, as 329 
estimated based on the participating centers, NPV was estimated at 81.3% (68-91%; 95% CI) 330 
and PPV at 83.2 (75-89%; 95% CI). Notably, the 116 biomarker panel enabled significant 331 
discrimination of UBC cases from controls regardless UBC TNM stage (Figure 2B; p<0.001, 332 
Kruskal-Wallis test, Table 2).  333 
Out of the 116 CE-MS derived peptide biomarkers, sequence could be obtained for 105 334 
peptides (i.e. 90.5%) listed in Supplementary Table S5). Most of the peptide sequences 335 
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(48/116 or 41%), were collagen fragments, possibly attributed to cancer-related processes 336 
(e.g. increased protease activity, extracellular matrix remodeling and increased collagen 337 
cleavage). The second most frequent sequences (14/116 or12%) originated from hemoglobin 338 
chains probably due to the presence of hematuria. Additional prominent peptides were derived 339 
from apolipoprotein A (5%), CD99 antigen (3%), fibrinogen A (2%), beta-2-microglobulin 340 
(2%), and single peptides from small proline-rich protein 3, insulin and histidine-rich 341 
glycoprotein. 342 
 343 
3.3 Validation of UBC biomarker panel for detection of recurrent UBC 344 
The 106 peptide biomarker panel for detection of recurrence was validated in 211 independent 345 
samples (including 55 UBC recurrent cases and 156 recurrent controls), with an AUC of 0.75, 346 
(95% CI: 0.68-0.80) (Figure 3A). At the ideal cut-off of -0.63, sensitivity and specificity 347 
values were 88% and 51%, respectively, while NPV was estimated at 93.6% (85-98%; 95% 348 
CI) and PPV at 32.32% (23-43%; 95% CI), accounting for a prevalence of 21.2% in the 349 
population investigated. 350 
 The classification scores of patients with recurrent UBC significantly differed from the 351 
negative for recurrence controls (p<0.001, Kruskal-Wallis test) (Figure 3B). The biomarker 352 
panel for detecting UBC recurrence also presented significant discriminatory ability between 353 
patients presenting with NMIBC (Ta, T1 and CIS: n=41, p<0.0001) and MIBC (T2-T4: n=14, 354 
p<0.0001), respectively (Table 2). 355 
For a substantial fraction of patients undergoing surveillance, data from the cytological 356 
examination of urine samples to evaluate presence of malignant cells, were available. Out of 357 
211 patients included in the validation phase, cytology had been performed in 96. Sensitivity 358 
and specificity of cytology for detecting recurrence was estimated at 31% and 100% 359 
respectively, while sensitivity of the classifier was 92% with a specificity of 53% in this 360 
subset of samples. Multivariate analysis, accounting for the available demographical variables 361 
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(age and gender) showed a superior AUC value of 0.80 for the classifier for detection of 362 
recurrence, compared to an AUC value of 0.69 obtained for cytology. Combination of both 363 
tests increased the performance, as assessed by an AUC of 0.87, compared to the 364 
performances of any single test alone (0.69 for cytology and 0.80 for the classifier -365 
Supplementary Table S6).  366 
The 106 peptide biomarker panel was further evaluated for detecting low risk recurrent UBC, 367 
as this represents a highly relevant biomarker context-of-use during disease surveillance of 368 
major anticipated added value to regular clinical practice (potentially decrease in number of 369 
cystoscopies [8]). For this assessment, 182 samples were available, including 26 UBC 370 
recurrent cases and 156 recurrent controls. An AUC of 0.72 (95% CI: 0.65-0.78) was 371 
observed (Supplementary Table S6). Cytological examination was available for 88 out of 372 
182 samples. The 106 peptide biomarker panel outperformed cytology, with an AUC of 0.79 373 
compared to an AUC of 0.64 for cytology. Combination of both tests increased the 374 
performance, as assessed by the given AUC of 0.90, compared to the performances of any 375 
single test alone, 0.64 for cytology and 0.79 for the classifier.  376 
Data on supplementary treatment (e.g. BCG or chemotherapy) administered prior to the urine 377 
collection were available for a total of 123 patients included in the validation set. Logistic 378 
regression analysis indicated that the classification score based on the 106 peptide biomarker 379 
was not affected by supplementary treatment (Supplementary Table S7). 380 
Out of 106 peptides included in the biomarker panel, 95 (89.6%) sequences were obtained 381 
(Supplementary Table S5). The majority (57%) were collagen fragments, while 382 
Apolipoprotein A-I peptides accounted for the second most frequent peptide sequences (6%). 383 
Other peptide biomarkers corresponded to fragments of basement membrane-specific heparan 384 
sulfate proteoglycan core protein (HSPG2), a disintegrin and metalloproteinase domain-385 
containing protein 22 (ADAM22), disintegrin and metalloproteinase with thrombospondin 386 
motifs 1 (ADAMTS1).  387 
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 388 
4. Discussion 389 
The present multi-center study optimized and validated two unique urinary peptide-based 390 
biomarker panels for detecting primary and recurrent UBC. The findings presented 391 
demonstrate the value of a multiple-marker approach for facilitating UBC diagnosis, 392 
particularly considering the increased variability which is likely caused in part by biological 393 
variability and by the high intra-tumor heterogeneity.   394 
The two classifiers were developed based on a pool of statistically significant different 395 
peptides. Even though these initial sets of shortlisted peptides did not largely overlap between 396 
the two cohorts, likely due to the applied stringent thresholds in each case (e.g. significant 397 
after BH adjustment, being consistent among centers), the final selected peptides forming the 398 
two classifiers are identical, with the exception of 10 hemoglobin fragments included solely in 399 
the “primary” classifier. Interestingly, out of these 116 peptide biomarkers, 56 were 400 
significantly correlated with disease stage and 32 with disease grade (Supplementary Table 401 
S8). Moreover, both peptide biomarker panels exhibited superior discriminatory ability in 402 
detecting MIBC compared to NMIBC (AUC of 0.94 for MIBC versus 0.84 for NMIBC for 403 
the 116 primary panel; AUC of 0.90 for MIBC and 0.70 for NMIBC for the 106-recurrent 404 
panel; Supplementary Table S8). Collectively these data suggest that the peptide biomarkers 405 
in their vast majority are reflective of changes associated with cancer progression, regardless 406 
whether that corresponds to a primary or relapsed event.  407 
Several of the biomarkers included in the classifiers were previously reported as biomarkers 408 
for the detection of UBC. Apolipoprotein A-I peptide fragments were found up-regulated in 409 
both primary and recurrent disease in line with earlier reported findings on this protein in 410 
UBC following application of two-dimensional electrophoresis (2-DE), or iTRAQ/LC-411 
MS/MS-based proteomics analysis (28-35). In addition, Fibrinogen chains α and β, well 412 
known urinary biomarkers for the detection of bladder cancer (30, 31, 33-35), were also 413 
Research. 
on April 11, 2016. © 2016 American Association for Cancerclincancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 29, 2016; DOI: 10.1158/1078-0432.CCR-15-2715 
17 
 
found at increased levels in urine from patients with UBC and included in the classifiers. 414 
Beta-2-macroglobulin and Basement membrane-specific heparan sulfate proteoglycan core 415 
protein (HSPG2) were also confirmed with decreased excretion levels in urine from patients 416 
with UBC, in line with previously reported proteomics data (28, 31, 33). Moreover, 417 
PGMRC1 (Membrane-associated progesterone receptor component 1) has been previously 418 
included as a peptide biomarker in a CE-MS classifier discriminating between NMIBC and 419 
MIBC patients (13). In the presented study, the same PGMRC1 peptide was detected at 420 
increased levels in urine of UBC patients, in comparison to controls. 421 
Of note, in the two biomarker panels for detection of primary and recurrent UBC, most 422 
peptide sequences were derived from collagen fragments. This likely reflects increased 423 
extracellular matrix (ECM) turnover, related to the activation of collagen-degrading proteases 424 
during tumor invasion (36). Several hemoglobin fragments were significantly associated with 425 
primary UBC, but not found to be significantly altered in the urine from patients presenting 426 
recurrence. This observation is in accordance with the hypothesis that hemoglobin fragments 427 
most likely indicate hematuria, which is frequently present in the urine of patients with 428 
primary tumours, but rarely in recurrence.  429 
Several peptide biomarkers included in the classifiers originate from proteins reported as 430 
associated with cancer initiation and/or progression. Small proline-rich protein 3 (SPPR3) 431 
was detected at higher levels in the urine of both primary and recurrent UBC patients, in 432 
comparison to controls. SPRR3 protein has not been characterized in the context of bladder 433 
cancer yet, however, up-regulation of SPRR3 protein levels promotes colorectal 434 
tumorigenesis (37) and is associated with tumour cell proliferation and invasion in 435 
glioblastoma (38). Additionally, 14-3-3 sigma protein is frequently down-regulated in a 436 
variety of human cancers including invasive UBC tumours, particularly in lesions 437 
undergoing Epithelial to Mesenchymal transition (39) and this down-regulation is attributed 438 
to increased methylation of its promoter (40). In the present study, fragments of 14-3-3 439 
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sigma were detected at lower urinary levels in patients with either primary or recurrent UBC 440 
in comparison to controls. Similarly, CD99 low protein expression levels, likely due to gene 441 
promoter hyper-methylation, have been also reported in UBC (41). In the present study, 442 
several peptides of CD99 protein were detected at lower levels in urine from patients with 443 
UBC, compared to controls.  444 
A small number  (about 10%) of the CE-MS ion peaks included in the classifiers could not be 445 
identified by MS/MS. Failure to obtain sequence from these peptides is generally due to either 446 
peptides not fragmenting well, or due to unknown post-translational modifications that 447 
prevent mapping to the available sequence databases (42). Since a higher number of 448 
biomarkers confers  increased stability of the test (12), the presented biomarker panels include 449 
all significant biomarkers identified, irrespective of whether the sequence was obtained, or 450 
not. Efforts are ongoing to obtain sequences from all peptides included in the discriminatory 451 
panels. 452 
For primary UBC, CE-MS derived urinary peptide biomarker panels were previously reported 453 
and assessed for detecting UBC (13). These studies, however, included lower number of 454 
samples and mostly MIBC cases (13). When investigating the performance of the previously 455 
reported classifier in additional cohorts mainly composed of NMIBC patients (13), the 456 
classifier exhibited 71% sensitivity and 40% specificity (data not shown), insufficient for 457 
clinical implementation.   458 
In our study, the source population and recruitment procedures very closely represent typical 459 
clinical situations. In such settings, high risk patients (e.g. with hematuria at primary 460 
diagnosis and/or under surveillance) are most likely to potentially benefit from the adoption of 461 
a non-invasive urine test, with a high NPV value, which could accurately guide cystoscopy (3, 462 
8). Considering the prevalence rates for the specific cohorts, the developed biomarker panels 463 
present an NPV value of 81.3% (68-91%; 95% CI) and PPV value of 83.2 (75-89%; 95% CI) 464 
for the primary and NPV of 93.6% (85-98%; 95% CI) and PPV of 32.32% (23-43%; 95% CI), 465 
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for the follow-up cohorts. These performance rates are at least as good as those of other UBC 466 
molecular markers which are FDA approved and/or are currently under investigation (6). A 467 
direct comparison of different markers and their performance, as reported in various studies is 468 
difficult, mainly due to differences in the clinical design of the respective studies. A 10-469 
biomarker ELISA-based assay (IL8, MMP9, MMP10, SERPINA1, VEGFA, ANG, CA9, 470 
APOE, SDC1, and SERPINE1) provided an overall AUC of 0.85 (95% CI, 0.80-0.91) in 471 
discriminating UBC patients from healthy and benign controls (45), slightly lower than the 472 
rates received from the CE-MS classifier for primary UBC (AUC=0.87; 95% CI 0.83-0.91). A 473 
three-gene methylation panel (OTX1, ONECUT2, and OSR1) detected low/ intermediate risk 474 
UBC with a sensitivity of 74% and specificity of 90% (43). In the present study, when 475 
investigating the sub-population of low/intermediate risk patients (NMIBC G1/G2; n=25), the 476 
CE-MS based classifier provided a sensitivity of 89% in UBC detection at the pre-selected 477 
cut-off (AUC of 0.72). For those low-intermediate risk patients where information on 478 
cytology was available (n=7), an increased sensitivity upon combination of the classifier with 479 
cytology could be obtained (AUC of 0.90; 100% sensitivity, 63% specificity).  Even though 480 
promising, this result is from a small subset of samples, therefore, its further validation is 481 
required. 482 
The strengths of the present investigation include that it is the largest multi-center study 483 
conducted to date for identifying and validating biomarker panels for primary and recurrent 484 
UBC. The presented urine-based biomarker panels hold promise for facilitating UBC 485 
diagnosis non-invasively in outpatient settings. The proteomics approaches applied for the 486 
biomarker panel development including use of an analytically validated platform (19) 487 
represent the current state-of-the-art, securing optimal diagnostic performance. The study 488 
design employed has diminished the potential effects of both source population and selection 489 
biases. Additionally, patient classification according to the standard of care, cystoscopy, 490 
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deters misclassification bias whilst enhancing the external validity and translational potential 491 
of study findings.  492 
However, several limitations are present in this study and warrant further consideration. 493 
Adjustment for potential confounding effects, including patient characteristics, clinical, and/or 494 
treatment variables, upon biomarker panel performance could not be conducted due to data 495 
limitations. In detail, clinical variables such as tumour size, multiplicity, presence of 496 
hematuria were not available for all samples.  497 
Moreover, multivariable regression analyses to predict UBC could not be performed, since 498 
known risk factors for UBC, including smoking history, previous upper tract cancer, and 499 
history or presence of macroscopic hematuria were also not recorded for all patients. 500 
Collectively, through the present study we aimed to meet a very clear clinical need in bladder 501 
cancer management: the development of biomarker assays to be used for diagnosis of bladder 502 
cancer and detection of disease recurrence, particularly among non-muscle invasive bladder 503 
cancer patients. Non-muscle invasive bladder cancer patients represent the largest bladder 504 
cancer subtype and also the group that would benefit most from improvement in recurrence 505 
monitoring procedures, as existing approaches are invasive. The specific impact of the non-506 
invasive biomarker classifiers would primarily be to guide cystoscopy and in combination 507 
with cytology as suggested by our results, and/or other molecular assays, reduce the number 508 
of surveillance cystoscopies. Moreover, in view of a positive test, urologists may be alerted to 509 
perform a more thorough investigation of the bladder hence increasing the overall accuracy in 510 
disease detection. 511 
Due to the applied cross-sectional study design, the presented findings should be confirmed in 512 
a prospective study. Further longitudinal investigations, accounting for potential confounding 513 
effects on biomarker performance could confirm the value of the present findings, and 514 
possibly allow detecting additional benefits (e.g. value in prognosis of progression). 515 
 516 
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5. Conclusions 517 
Two urine-based biomarker panels for detecting primary and recurrent UBC were developed 518 
to support patient screening and monitoring. The urine-based biomarkers for primary UBC 519 
hold promise for facilitating UBC diagnosis non-invasively in outpatient settings. The urine-520 
based panel for detecting recurrence in combination to cytology resulted in improved non- 521 
invasive UBC detection. Additional prospective investigations accounting for potential 522 
confounding effects are planned to evaluate potential clinical implementation. 523 
 524 
Figure Legends  525 
Figure 1: Schematic representation of the study design and the analytical workflow for the 526 
development of urine-based biomarker panels. As shown in the schema, a discovery and 527 
validation phase was followed for the urine-based biomarker panels, for detecting a) primary 528 
UBC, as shown in the left arm of the schema and b) recurrent UBC, as displayed in the right 529 
arm of the schema. UBC= urothelial bladder cancer. 530 
 531 
Figure 2: A) Receiver operating characteristics (ROC) analysis performed in the independent 532 
validation cohort, displaying the performance of the UBC model for classifying the primary 533 
UBC cases and B) the respective classification scores, presented in Box-and-Whisker plots 534 
according to the NMIBC (n=115) and MIBC (n=53) stages of the primary UBC cases.  The 535 
UBC model was constructed based on 116 bladder cancer specific peptides. Other ROC 536 
characteristics, such as area under the curve (AUC), 95% confidence intervals (CI), and p 537 
value are provided for the classification of UBC patients.  AUC, area under the curve; CI, 538 
confidence intervals, ROC, receiver operating characteristics; UBC, Urothelial bladder 539 
cancer. 540 
 541 
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Figure 3: A) Receiver operating characteristics (ROC) curve for the urinary biomarker panel, 542 
consisting of 106 peptides as performed in the independent validation cohort. The area under 543 
the curve (AUC), 95% confidence intervals (CI), and p value are also provided for the 544 
classification of UBC patients. B) Classification scores presented in Box-and-Whisker 545 
displaying the level of discrimination between the recurrent UBC cases and negative for UBC 546 
control and the distribution of classification values for NMIBC (n=41) and MIBC cases 547 
(n=14). A post-hoc rank-test was performed using Kruskal-Wallis test. The average rank 548 
differences were significantly different (p<0.05) between the controls and the recurrent UBC 549 
case group. UBC, Urothelial bladder cancer.  550 
 551 
 552 
 553 
 554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
 565 
 566 
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Table 1 - Patient cohorts and samples sizes involved in the different study phases 568 
 569 
 Sample sizen=1357 (%) Age (SD)
‡ 
Study Arm I: Discovery and validation of 
biomarker panel for primary UBC 
721 66(±13) 
Overall primary UBC patients  509 (71%) 68(±12)  
Overall urological controls 212 (29%) 63(±15)  
Discovery Phase  451 66(±13) 
Primary UBC patients  341 (76%) 67(±12)  
Urological controls 110 (24%) 60(±16)  
Validation Phase  270 68(±12) 
Primary UBC patients  168 (62%) 69(±11)  
Urological Controls  102 (38%) 65(±14)  
Study Arm II: Discovery and validation of 
biomarker panel for recurrent UBC  
636 68 (±12) 
Overall UBC patients with recurrent disease 164 (26%) 70± (11) 
Overall UBC patients without recurrent 
disease (“recurrent controls”)  
472 (74%) 68± (12) 
Discovery Phase  425 69(±12) 
UBC patients with recurrent 
disease 
109 (26%) 71± (10) 
UBC patients without recurrent 
disease  
316 (74%) 68± (12) 
Validation Phase  211 68(±13) 
UBC patients with recurrent 
disease 
55 (26%) 69± (13) 
UBC patients without recurrent 
disease 
156 (74%) 68± (13) 
UBC; Urothelial Bladder Cancer 
‡Mean Value 
 570 
 571 
Table 2 - Classification scores of the biomarker panels for NNMIBC and MIBC, as obtained 572 
during the independent validation phase. The urinary biomarker panel of 116 peptides was 573 
developed for the detection of primary UBC patients and the urinary biomarker panel of 106 574 
was optimized for detecting recurrent UBC patients.  575 
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 576 
 577 
 578 
 
Urinary biomarker panel for the 
detection of Primary UBC  
Urinary biomarker panel for the 
detection of Recurrent UBC
 (diagnosis†) Sample Size n=270, (%)‡  
Classification 
score  
mean value 
(SD) 
p value¥    
Sample Size 
n=211 , (%)    
Classification 
score 
mean value 
(SD) 
p value) ¥ 
NMIBC         
  (Ta, T1, CIS††) 115 (42.6%) 0.29(0.54) <0.0001  41 (19.4%) -0.18 (0.48) <0.0001 
MIBC 53 (19.6%) 0.58(0.32) <0.0001  14 (6.7%) 0.10 (0.50) <0.0001 
ControlsII  102 (37.8%) -0.69(0.82)   156 (73.9%) -0.56 (0.48)   
 
 
II For the primary UBC, the controls are referring to urological controls (hematuria, benign urological diseases), while in 
the recurrent group, the controls included are samples derived from patients negative for recurrence.  
† According to the 2004 TNM system (18); †† According to EAU guidelines (3, 44); ‡ Percentage over the number of UBC 
cases; ¥ Independent samples T-Test. 
MIBC = muscle invasive bladder cancer; NMIBC = non muscle invasive bladder cancer; UBC = urothelial bladder cancer.
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